PE20070106A1 - Composiciones farmaceuticas que contienen un inhibidor de la proteasa hcv y un competidor akr - Google Patents

Composiciones farmaceuticas que contienen un inhibidor de la proteasa hcv y un competidor akr

Info

Publication number
PE20070106A1
PE20070106A1 PE2006000589A PE2006000589A PE20070106A1 PE 20070106 A1 PE20070106 A1 PE 20070106A1 PE 2006000589 A PE2006000589 A PE 2006000589A PE 2006000589 A PE2006000589 A PE 2006000589A PE 20070106 A1 PE20070106 A1 PE 20070106A1
Authority
PE
Peru
Prior art keywords
alkyl
absent
pharmaceutical compositions
compositions containing
present
Prior art date
Application number
PE2006000589A
Other languages
English (en)
Inventor
Anima Ghosal
Narendra S Kishnani
Kevin B Alton
Ronald E White
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20070106A1 publication Critical patent/PE20070106A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN COMPETIDOR DE LA ALDO-CETO REDUCTASA (AKR) SELECCIONADO ENTRE DOLASETRON, DOXORUBICINA, FIBRATO, ANTIINFLAMATORIO NO ESTEROIDE, ENTRE OTROS; B) UN COMPUESTO, ENTRE OTROS, DE FORMULA I, DONDE Y ES ALQUILO, ALQUIL-ARILO, ALQUILOXI, ARILOXI, HETEROARILAMINO, ENTRE OTROS; R1 ES COCONHR9; R9 ES H, ALQUILO, ARILO, HETEROALQUILO, CICLOALQUILO, ENTRE OTROS; Z ES O, N, CH, ENTRE OTROS; W PUEDE ESTAR AUSENTE O NO Y ES CO, CS, SO2, ENTRE OTROS; Q ES CH, P, S, SO2, ENTRE OTROS; A ES O, CH2, S, SO2, UN ENLACE, ENTRE OTROS; E ES CH, N, UN ENLACE DOBLE HACIA A, L, G, ENTRE OTROS; G ESTA PRESENTE O AUSENTE Y ES (CH2)p, (CHR)p, NR, ENTRE OTROS; J ES (CH2)p, (CHR)p, SO2, NH, NR, O, ENTRE OTROS; L ES PUEDE ESTAR PRESENTE O AUSENTE Y ES CH, CR, O, S, NR; M PUEDE ESTAR PRESENTE O AUSENTE Y ES O, NR, S, SO2, (CH2)p, ENTRE OTROS; p ES 0-6; R, R2, R3 Y R4 SON CADA UNO H, ALQUILO C1-C10, ALQUENILO C2-C10, CICLOALQUILO C3-C8, ALCOXI, ENTRE OTROS. UN COMPUESTO PREFERIDO ES A. DICHAS COMPOSICIONES SON UTILES EN EL TRATAMIENTO O PREVENCION DE LA HEPATITIS C Y DESORDENES RELACIONADOS CON EL VIRUS VHC
PE2006000589A 2005-06-02 2006-06-01 Composiciones farmaceuticas que contienen un inhibidor de la proteasa hcv y un competidor akr PE20070106A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68692405P 2005-06-02 2005-06-02

Publications (1)

Publication Number Publication Date
PE20070106A1 true PE20070106A1 (es) 2007-04-16

Family

ID=36954846

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000589A PE20070106A1 (es) 2005-06-02 2006-06-01 Composiciones farmaceuticas que contienen un inhibidor de la proteasa hcv y un competidor akr

Country Status (5)

Country Link
US (1) US20060276404A1 (es)
AR (1) AR054197A1 (es)
PE (1) PE20070106A1 (es)
TW (1) TW200724154A (es)
WO (1) WO2006130666A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US8119602B2 (en) * 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
JP5249028B2 (ja) * 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
DE602006019323D1 (de) 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20070287664A1 (en) * 2006-03-23 2007-12-13 Schering Corporation Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
MX2008013119A (es) 2006-04-11 2008-10-21 Novartis Ag Inhibidores de hcv/vih y sus usos.
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR066528A1 (es) 2007-05-10 2009-08-26 Array Biopharma Inc Peptidos inhibidores de la replicacion del virus de la hepatitis c
AR068756A1 (es) 2007-10-10 2009-12-02 Novartis Ag Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c
EP2222324A2 (en) * 2007-11-20 2010-09-01 Concert Pharmaceuticals, Inc. Boceprevir derivatives for the treatment of hcv infections
AU2008340261C1 (en) 2007-12-21 2015-12-10 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
KR101683559B1 (ko) 2007-12-21 2016-12-08 셀진 아빌로믹스 리서치, 인코포레이티드 Ｈｃｖ 프로테아제 억제제 및 이의 용도
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2300491B1 (en) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
WO2010138889A1 (en) 2009-05-28 2010-12-02 Concert Pharmaceuticals, Inc. Peptides for the treatment of hcv infections
PE20140039A1 (es) 2010-12-30 2014-03-01 Enanta Pharm Inc Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102836433A (zh) * 2011-06-23 2012-12-26 北京大学 逆转或降低食管癌放疗抗性的增敏剂、筛选方法及其用途
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CH707030B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
UY34402A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
WO2014033667A1 (en) * 2012-08-30 2014-03-06 Ranbaxy Laboratories Limited Process for the preparation of telaprevir
ES2613766T3 (es) 2012-10-19 2017-05-25 Bristol-Myers Squibb Company Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2-a)(1,4)diazaciclopentadecinilo sustituidos con 9-metilo como inhibidores de la proteasa no estructural 3 (NS3) para el tratamiento de infecciones del virus de la hepatitis C
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
CN110220757B (zh) * 2019-06-05 2021-08-24 浙江龙传生物医药科技有限公司 用于药物代谢检测的血液保存剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04023B1 (et) * 1996-10-18 2003-04-15 Vertex Pharmaceuticals Incorporated Seriinproteaaside, eriti C-hepatiidi viiruse NS3-proteaasi inhibiitorid
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6767991B1 (en) * 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
CA2410682A1 (en) * 2000-07-21 2002-01-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
ATE443703T1 (de) * 2002-01-23 2009-10-15 Schering Corp Prolinderivate als ns3-serine protease hemmer, zur verwendung bei der bekämpfung von hepatitis c virusinfektion
AR044694A1 (es) * 2003-06-17 2005-09-21 Schering Corp Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
JP4823899B2 (ja) * 2003-06-17 2011-11-24 シェーリング コーポレイション ３−（アミノ）−３−シクロブチルメチル−２−ヒドロキシ−プロピオンアミドまたはその塩の調製のためのプロセスおよび中間体
US7309717B2 (en) * 2003-06-17 2007-12-18 Schering Corporation Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof
EP1664090A2 (en) * 2003-08-26 2006-06-07 Schering Corporation Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
CN1902216A (zh) * 2003-11-20 2007-01-24 先灵公司 丙肝病毒ns3蛋白酶的去肽化抑制剂
WO2005058821A1 (en) * 2003-12-11 2005-06-30 Schering Corporation Inhibitors of hepatitis c virus ns3/ns4a serine protease
US7205330B2 (en) * 2004-02-27 2007-04-17 Schering Corporation Inhibitors of hepatitis C virus NS3 protease
US7173057B2 (en) * 2004-02-27 2007-02-06 Schering Corporation Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus
JP2007525510A (ja) * 2004-02-27 2007-09-06 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしての化合物
DE602005015093D1 (de) * 2004-02-27 2009-08-06 Schering Corp Neue verbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
DE602005021760D1 (de) * 2004-02-27 2010-07-22 Schering Corp Schwefelverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
ATE438622T1 (de) * 2004-02-27 2009-08-15 Schering Corp 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
CN1946690A (zh) * 2004-02-27 2007-04-11 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的含环丁烯二酮基团化合物
WO2005113581A1 (en) * 2004-05-20 2005-12-01 Schering Corporation Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease

Also Published As

Publication number Publication date
WO2006130666A3 (en) 2007-06-21
WO2006130666A2 (en) 2006-12-07
AR054197A1 (es) 2007-06-06
TW200724154A (en) 2007-07-01
US20060276404A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
PE20070106A1 (es) Composiciones farmaceuticas que contienen un inhibidor de la proteasa hcv y un competidor akr
PE20080197A1 (es) Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s)
UY29016A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
PE20050370A1 (es) Inhibidores peptidomimeticos novedosos de la serina proteasa ns3 del virus de la hepatitis c
PE20050999A1 (es) Cetoamidas novedosas con p4 ciclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c
PE20030852A1 (es) Peptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c
ECSP066456A (es) Inhibidores macrocíclicos de la serina proteasa ns3 del virus de la hepatitis c
PE20070011A1 (es) Formulaciones farmaceuticas de compuestos inhibidores de proteasa del vhc o catepsina
PE20080457A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasas de hepatitis c
PE20020188A1 (es) COMPUESTOS MACROCICLICOS COMO INHIBIDORES DE LA SERINA PROTEASA NS3/NS4a DEL VIRUS DE LA HEPATITIS C (VHC)
ATE334654T1 (de) Vor uv-strahlen schützende zusammensetzungen
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
PE20070343A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
CO5580746A2 (es) Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina
NO20075809L (no) DNA-PK inhibitorer
PE20050013A1 (es) Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c
BRPI0606480A (pt) compostos farmacêuticos
NO20080879L (no) HCV-NS3-proteaseinhibitorer
EA200702080A1 (ru) Полициклическое карбомоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
AR057325A1 (es) Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
MX2010003261A (es) Analogos de azacitidina y usos de los mismos.
NO20091706L (no) Inhibitorer av hepatitt C virus
AR061858A1 (es) Compuestos heterociclicos de fosfonatos y fosfinatos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos.
ECSP045224A (es) Tripéptidos inhibidores de la hepatitis c

Legal Events

Date Code Title Description
FA Abandonment or withdrawal